Footnotes are at the end of the report. It's not possible to post the 500 or so pages of exhibits here on my blog, but those interested in reviewing the actual studies cited should contact NYTHA.
Depo-Medrol is a particularly potent and long-lasting corticosteroid, generally administered by injection as an anti-inflammatory to address musculoskeletal conditions, including the pain and lameness associated with acute localized arthritic conditions and general arthritis. It has also been used to treat equine rheumatoid arthritis, osteoarthritis, periostitis, synovitis, tenosynovitis, tendinitis and bursitis. Other corticosteroids, both topical and injectable, are often used to treat arthritis-type conditions and a wide variety of other conditions.
Because corticosteroids are treatments of existing medical conditions, rather than preventatives like Lasix, NYTHA opposes their use on raceday. Generally, a four-day withdrawal period should be adequate to ensure removal of the medications from a horse’s system, although the American Quarter Horse Association and the US Equestrian Federation mandate a seven-day withdrawal period before competing. Because of Depo-Medrol’s long-lasting effect, we would suggest a 15-day withdrawal period.
A majority of trainers use clenbuterol, which is not a steroid, but rather a bronchodilator and decongestant, from time to time in training to ensure that their horses have clean airways. Because clenbuterol, like other medications that are banned on raceday, treats an existing condition, we support the ban on its use. We believe, based on the veterinary evidence and discussions with Dr. George Maylin, that a seven-day withdrawal period would be adequate to ensure that clenbuterol would have no material effect on raceday.
As these suggestions show, NYTHA fully supports rational, fact-based efforts to limit medication use on the racetrack and to assure a level playing field. What we do not support is making medication decisions based on feelings or intuition that fly in the face of the scientific evidence.
- Sudden death attributable to exercise-induced pulmonary hemorrhage in racehorses: Nine cases (1981-83)
- “AAEP” PUTTING THE HORSE FIRST: VETERINARY RECOMMENDATIONS FOR THE SAFETY AND WELFARE OF THE THOROUGHBRED RACEHORSE
- “AAEP” CLINICAL GUIDELINES FOR VETERINARIANS PRACTICING IN A PARI-MUTUEL ENVIRONMENT
- TO RACE OR NOT TO RACE: THE LASIX ETHICAL DILEMMA
- Exercise-Induced Pulmonary Hemorrhage in Horses: the Role of Pulmonary Veins
- Letter from Thomas Tobin, DVM re bone weakening. 12/7/2011
- Fracture risk in patients treated with loop diuretics
- Dr. McNamara Letter to NYSRWB 5/5/12
- Summary of Bleeder Data from Hong Kong Jockey Club
- RCI: RACING’S DRUG “PROBLEM” OVERSTATED
- U.S. ANTI-DOPING AGENCY: ATHLETE HANDBOOK AND EXAMPLES OF MEDICATIONS